PSMA PET/CT Scans Show Promise in Tailoring Prostate Cancer Recurrence Treatment
Event summary
- UCLA researchers found PSMA PET/CT scans can predict progression-free survival (PFS) and guide treatment for recurring prostate cancer post-surgery.
- Study analyzed 113 patients, showing WPRT improved PFS for local disease but not for no visible disease; ADT benefited metastatic cases.
- PSA levels alone were not strongly associated with long-term treatment response.
- Research published in the February 2026 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
The big picture
The study underscores the growing role of advanced imaging in precision oncology, particularly in tailoring treatments for cancer recurrence. As healthcare systems increasingly prioritize personalized medicine, the findings could influence both clinical practice and reimbursement policies for prostate cancer care. The research also highlights the potential to reduce unnecessary treatments and side effects, aligning with broader trends in value-based healthcare.
What we're watching
- Clinical Adoption
- How quickly PSMA PET/CT scans will be integrated into standard care protocols for prostate cancer recurrence.
- Treatment Personalization
- Whether the findings will accelerate the shift from one-size-fits-all to personalized radiation therapy approaches.
- Regulatory Impact
- The pace at which regulatory bodies may update guidelines to reflect the use of PSMA PET/CT scans in treatment planning.
Related topics